Testing prasinezumab in early Parkinson’s

Researchers are checking the effects and safety of the study medicine prasinezumab, given through a vein, compared with an inactive treatment.

Testing a treatment or activity · Study reference: NCT07174310

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Who can join?

Ages 50 years to 85 years · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Reference Study ID Number: BN44715 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.